Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (295)	12/11/2007 5:11:04 PM
From: DewDiligence_on_SI	Read Replies (1) of 684

Eyeballing the list from November it looks like strong bounces in NUVO and ADLR, nothing else too notable. All NUVO has done lately is present the data from the (failed) phase-3 catheter-occlusion trial at ASH, and the top-line data from this trial were reported many months ago. If investors are thinking more positively about Alfimeprase in light of the ASH presentation, I’m not sure exactly why.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next